MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancer

Treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer, the most common type of breast cancer, has faced challenges such as endocrine therapy resistance and distant relapse. Immunotherapy has shown progress in treating triple-negative brea...

Full description

Bibliographic Details

Published in:	The Journal of Clinical Investigation
Main Authors:	Yu-Wen Cai, Cui-Cui Liu, Yan-Wu Zhang, Yi-Ming Liu, Lie Chen, Xin Xiong, Zhi-Ming Shao, Ke-Da Yu
Format:	Article
Language:	English
Published:	American Society for Clinical Investigation 2025-01-01
Subjects:	Immunology Oncology
Online Access:	https://doi.org/10.1172/JCI183656